Hospitals Want Role in Three More Pharma Lawsuits Over 340B Contract Pharmacy

Hospital groups want to intervene in opposition to three more drug manufacturers' lawsuits against the federal government over 340B contract pharmacy requirements.

Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,

Read More »

Senator Cassidy Again Cites 340B in Opposing Becerra for HHS Secretary

U.S. Sen. Bill Cassidy (R-La.) yesterday criticized HHS Secretary-designate Xavier Becerra's lack of familiarity with 340B before voting in the Finance Committee against reporting Becerra's nomination favorably to the full Senate.

The U.S. Senate Finance Committee yesterday split 14-14 along party lines on whether to favorably report California Attorney General Xavier Becerra’s nomination to serve as U.S. Health and Human Services (HHS) secretary to the full Senate.

There is a 50-50

Read More »

A Recap of the Acentrus Specialty Conference

SPONSORED CONTENT

Acentrus Specialty hosted its first Acentrus Specialty Conference on January 12-13, 2021, which brought together pharmacists, manufacturers, and suppliers to examine the challenges, opportunities, and best practices in advancing health system specialty pharmacy practice. A pharmacy paradigm shift is under way, as Integrated Delivery Networks (IDNs) are partnering to grow their specialty pharmacy operations.

“The conference

Read More »

Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption

Humira, one of the 15 partial orphan drugs examined in the new study in Health Affairs, had $13.7 billion in sales in 2018.

More than 70 percent of U.S. spending on top-selling “partial orphan drugs”—drugs for rare diseases that also are approved to treat common diseases—is for non-orphan indications, a study in latest edition of Health Affairs concludes.

Makers of partial orphan drugs

Read More »

Senate Democrats Soften, But Don’t Yank, COVID Relief Bill’s Medicaid Rebate Language

In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling

Read More »

340B Report Publisher/CEO: Look for a Return to an Era of 340B Guidance

Recent developments in federal court bode well for 340B providers trying to restore access to 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO Ted Slafsky’s take in his latest column for the Omnicell blog

The Biden administration’s embrace of the federal government’s traditional stance on the enforceability of program guidance—which the Trump administration rejected—may lead to stronger enforcement of 340B program guidance and possibly even the issuance of new 340B guidelines, 340B Report Publisher

Read More »

DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle

The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.

First, on Feb. 16 in a federal district court in

Read More »

340B Providers Cheer Bipartisan House Letter to HHS on Manufacturer Actions

Safety-net hospitals, health centers, and HIV/AIDS clinics yesterday applauded the 226 U.S. representatives—more than half of the House’s members—who signed Friday’s bipartisan letter to U.S. Health and Human Services (HHS) Acting Secretary Norris Cochran seeking “immediate action to ensure that

Read More »

N.Y. and Calif. 340B Pharmacies Get Reprieve From Medicaid Cuts

New York State and California’s nationally watched efforts to transfer their pharmacy programs for low-income individuals from Medicaid managed care to Medicaid fee for service (FFS)—both scheduled to take effect on April 1—have been temporarily placed on hold. The states

Read More »

Huge COVID Relief Bill That Would Lift Medicaid Rebate Caps Moves to Senate

The U.S. House on Saturday passed a $1.9 trillion COVID-19 relief bill with language that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).

The bill, H.R. 1319,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live